| Identification | Back Directory | [Name]
RTI-118 | [CAS]
847554-50-1 | [Synonyms]
RTI-118
3H-Oxazolo[3,4-a]pyrazine-7(1H)-carboxamide, tetrahydro-3-oxo-1,1-diphenyl-N-[2-(1-piperidinyl)ethyl]- | [Molecular Formula]
C26H32N4O3 | [MDL Number]
MFCD30536600 | [MOL File]
847554-50-1.mol | [Molecular Weight]
448.56 |
| Hazard Information | Back Directory | [Uses]
RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve agent addiction including selectively decrease self-administration[1]. | [in vivo]
RTI-118 (5-30 mg/kg, intraperitoneal injection; pre-30 minutes) is well tolerated in rats with no significant outward signs of aversion, sedation or toxicity, it also produces a dose-related decrease in food self-administration[1]. | Animal Model: | Rat[1] | | Dosage: | 5 mg/kg; 10 mg/kg; 20 mg/kg; 30 mg/kg | | Administration: | Intraperitoneal?injection; pre-treatment 30 minutes; 5-30 mg/kg | | Result: | The effects on the reinstatement of seeking behavior are restricted to doses of 20 mg/kg or less. |
| [References]
[1] Schmoutz CD, et al.Antagonism of the neuropeptide S receptor with RTI-118 decreases cocaine self-administration and cocaine-seeking behavior in rats.Pharmacol Biochem Behav. 2012 Dec;103(2):332-7. DOI:10.1016/j.pbb.2012.09.003
[2] Bonano JS,et al. Effects of the neuropeptide S receptor antagonist RTI-118 DOI:10.1016/j.ejphar.2014.09.006 |
|
|